Mfn2 levels have been found to be decreased in liver samples from NASH patients and in mouse models of steatosis and NASH; Mfn2 re-expression has been reported to improve disease in NASH mouse models, while the liver-specific deletion of Mfn2 causes inflammation, triglyceride accumulation, fibrosis, and liver cancer [197]. Here, MFN2 is linked to steatosis.